Covidien says FDA extends Exalgo review
Covidien says FDA extends review on pain drug Exalgo to Feb. 22 Health care company Covidien PLC said Friday the Food and Drug Administration will take longer than expected to review the potential opioid pain drug Exalgo. The agency said it is ...